Background: Tranexamic acid prevents fibrinolysis by blocking the lysine binding sites on plasminogen molecules. Its a safe and efficient supplement to other uterotonics already in use to reduce bleeding during and after LSCS. Material and Methods: 500 patinets grouped into cases and controls were taken, cases were given Tranexamic acid in addition to third stage management and blood loss was calculated by gravimetric method and changes in hematocrit in both groups. Patients vitals were monitored and checked for any adverse drug reactions. Patients with medical, surgical complications, blood disorders, h/o allergy to TXA, abnormal placentations, multiple pregnancies, polyhydramnios, pregnancy with myoma were excluded from the study along with those who were transfused blood within 24hrs of LSCS. Results: Tranexamic acid significantly reduces bleeding from time of placental delivery to 2 hours postpartum in LSCS, similar to studies done by Gohel-Mayer, Yehia, Goswami, Goswami and others. Conclusion: Tranexamic acid has been shown to significantly reduce the amount of blood loss during & after lower segment cesarean section without any serious adverse effects